PE20180241A1 - Adenovirus oncolitico que codifica una proteina b7 - Google Patents

Adenovirus oncolitico que codifica una proteina b7

Info

Publication number
PE20180241A1
PE20180241A1 PE2017002327A PE2017002327A PE20180241A1 PE 20180241 A1 PE20180241 A1 PE 20180241A1 PE 2017002327 A PE2017002327 A PE 2017002327A PE 2017002327 A PE2017002327 A PE 2017002327A PE 20180241 A1 PE20180241 A1 PE 20180241A1
Authority
PE
Peru
Prior art keywords
protein
virus
oncolytic adenovirus
compositions
treatment
Prior art date
Application number
PE2017002327A
Other languages
English (en)
Spanish (es)
Inventor
Brian Robert Champion
Alice Claire Noel Bromley
Original Assignee
Psioxus Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1507419.8A external-priority patent/GB201507419D0/en
Priority claimed from GBGB1516936.0A external-priority patent/GB201516936D0/en
Priority claimed from GBGB1522013.0A external-priority patent/GB201522013D0/en
Application filed by Psioxus Therapeutics Ltd filed Critical Psioxus Therapeutics Ltd
Publication of PE20180241A1 publication Critical patent/PE20180241A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/761—Adenovirus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C12N15/861—Adenoviral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/521—Chemokines
    • C07K14/523—Beta-chemokines, e.g. RANTES, I-309/TCA-3, MIP-1alpha, MIP-1beta/ACT-2/LD78/SCIF, MCP-1/MCAF, MCP-2, MCP-3, LDCF-1, LDCF-2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/56—IFN-alpha
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70532—B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/035—Fusion polypeptide containing a localisation/targetting motif containing a signal for targeting to the external surface of a cell, e.g. to the outer membrane of Gram negative bacteria, GPI- anchored eukaryote proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10321—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10332—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10371—Demonstrated in vivo effect

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
PE2017002327A 2015-04-30 2016-04-29 Adenovirus oncolitico que codifica una proteina b7 PE20180241A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1507419.8A GB201507419D0 (en) 2015-04-30 2015-04-30 Virus
GBGB1516936.0A GB201516936D0 (en) 2015-09-24 2015-09-24 Virus
GBGB1522013.0A GB201522013D0 (en) 2015-12-14 2015-12-14 Virus

Publications (1)

Publication Number Publication Date
PE20180241A1 true PE20180241A1 (es) 2018-01-31

Family

ID=56008588

Family Applications (2)

Application Number Title Priority Date Filing Date
PE2018000519A PE20181140A1 (es) 2015-04-30 2016-04-29 Adenovirus oncolitico que codifica una proteina b7
PE2017002327A PE20180241A1 (es) 2015-04-30 2016-04-29 Adenovirus oncolitico que codifica una proteina b7

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PE2018000519A PE20181140A1 (es) 2015-04-30 2016-04-29 Adenovirus oncolitico que codifica una proteina b7

Country Status (31)

Country Link
US (6) US11000559B2 (enExample)
EP (2) EP3288573B1 (enExample)
JP (3) JP6931229B2 (enExample)
KR (4) KR102854512B1 (enExample)
CN (2) CN107690479B (enExample)
AU (3) AU2016256582B2 (enExample)
BR (2) BR112017023171A2 (enExample)
CA (1) CA2984038C (enExample)
CL (2) CL2017002731A1 (enExample)
CO (1) CO2017010831A2 (enExample)
CY (1) CY1122833T1 (enExample)
DK (1) DK3288573T3 (enExample)
EA (1) EA037611B1 (enExample)
ES (1) ES2780366T3 (enExample)
HR (1) HRP20200439T1 (enExample)
HU (1) HUE048320T2 (enExample)
IL (3) IL284375B (enExample)
LT (1) LT3288573T (enExample)
MX (1) MX2017013684A (enExample)
MY (1) MY183703A (enExample)
PE (2) PE20181140A1 (enExample)
PH (1) PH12017501942A1 (enExample)
PL (1) PL3288573T3 (enExample)
PT (1) PT3288573T (enExample)
RS (1) RS60105B1 (enExample)
SA (2) SA517390260B1 (enExample)
SG (3) SG10201803081TA (enExample)
SI (1) SI3288573T1 (enExample)
SM (1) SMT202000222T1 (enExample)
WO (1) WO2016174200A1 (enExample)
ZA (1) ZA201801589B (enExample)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112015030881A2 (pt) 2013-06-14 2017-10-24 Psioxus Theraupeutics Ltd “regime de dosagem e formulações para adenovírus de tipo b”
GB201322851D0 (en) 2013-12-23 2014-02-12 Psioxus Therapeutics Ltd Method
LT3021859T (lt) 2013-10-25 2018-06-11 Psioxus Therapeutics Limited Onkolitiniai adenovirusai su heterologiniais genais
GB201406608D0 (en) 2014-04-12 2014-05-28 Psioxus Therapeutics Ltd Virus
HRP20200439T1 (hr) 2015-04-30 2020-06-12 Psioxus Therapeutics Limited Onkolitički adenovirus koji kodira protein b7
BR112018008865A8 (pt) 2015-11-02 2019-02-26 Five Prime Therapeutics Inc polipeptídeos do domínio extracelular cd80 e seu uso no tratamento do câncer
MY193281A (en) * 2015-12-17 2022-09-30 Psioxus Therapeutics Ltd Group b adenovirus encoding an anti-tcr-complex antibody or fragment
SI3436591T1 (sl) * 2016-03-31 2023-05-31 The European Molecular Biology Laboratory Dostavni vehikli, izpeljani iz proteina adenovirusne ovojnice
GB201713765D0 (en) 2017-08-28 2017-10-11 Psioxus Therapeutics Ltd Modified adenovirus
KR102427563B1 (ko) 2016-08-29 2022-08-03 싸이오서스 테라퓨틱스 엘티디. 이중특이성 T 세포 활성화제(Bispecific T cell activator)가 보강된 아데노바이러스
EP4282969A3 (en) 2016-09-02 2024-01-31 Lentigen Technology, Inc. Compositions and methods for treating cancer with duocars
CN117085047A (zh) * 2016-09-27 2023-11-21 萨特治疗学有限公司 优化的溶瘤病毒及其用途
WO2018083258A1 (en) * 2016-11-03 2018-05-11 Psioxus Therapeutics Limited Oncolytic adenovirus encoding at least three transgenes
WO2018083257A1 (en) * 2016-11-03 2018-05-11 Psioxus Therapeutics Limited Oncolytic adenovirus encoding transgenes
WO2018083259A1 (en) * 2016-11-03 2018-05-11 Psioxus Therapeutics Limited Oncolytic adenovirus encoding transgenes
EP3577132A4 (en) * 2017-02-03 2021-03-10 University of Pittsburgh - of The Commonwealth System of Higher Education ONCOLYTIC VIRUS THERAPY
MX2019012849A (es) 2017-04-28 2019-11-28 Five Prime Therapeutics Inc Metodos de tratamiento con polipeptidos del dominio extracelular del cd80.
BR112019024656A2 (pt) * 2017-05-25 2020-06-09 Univ Central Florida Res Found Inc vírus oncolíticos para a sensibilização de células tumorais para morte por células exterminadoras naturais
NZ759833A (en) * 2017-05-26 2023-01-27 Epicentrx Inc Recombinant adenoviruses carrying transgenes
CN118308311A (zh) * 2017-06-01 2024-07-09 阿卡米斯生物公司 溶瘤病毒和方法
WO2019147921A1 (en) 2018-01-26 2019-08-01 Nantcell, Inc. Rapid verification of virus particle production for a personalized vaccine
GB201801614D0 (en) * 2018-01-31 2018-03-14 Psioxus Therapeutics Ltd Formulation
WO2019173334A1 (en) * 2018-03-05 2019-09-12 The Schepens Eye Research Institute, Inc. Engineered vegf variants for retinal neuroprotection, promotion of axon growth and axon regeneration
KR20200136972A (ko) * 2018-03-30 2020-12-08 도모키 도도 종창 발생 억제형 종양 용해성 바이러스
JP2022502074A (ja) * 2018-09-10 2022-01-11 ジェネセイル バイオテック（シャンハイ）カンパニー リミテッド 改変された腫瘍溶解性ウイルス、組成物、およびその使用
CN113439123A (zh) * 2019-03-05 2021-09-24 安进公司 溶瘤病毒用于治疗癌症的用途
EP3725323A1 (en) * 2019-04-17 2020-10-21 Targovax Asa Oncolytic adenoviral vector expressing a member of the b7 family of costimulatory ligands and ada
IL322315A (en) 2019-05-14 2025-09-01 Provention Bio Inc Methods and preparations for preventing type 1 diabetes
EP3970754A4 (en) * 2019-05-14 2023-08-02 Oncolys BioPharma, Inc. METHOD OF ADMINISTRATION OF ONCOLYTIC VIRUS TO TUMOR TISSUE AND DEVICE FOR ADMINISTRATION
GB201909081D0 (en) 2019-06-25 2019-08-07 Psioxus Therapeutics Ltd Method
MX2022015872A (es) 2020-06-11 2023-05-16 Provention Bio Inc Metodos y composiciones para prevenir diabetes tipo 1.
GB202102049D0 (en) * 2021-02-13 2021-03-31 Psioxus Therapeutics Ltd Viruses
EP4332218A4 (en) * 2021-06-03 2024-09-18 Shanghai Yunying Biopharmaceutical Technology Co., Ltd. ONCOLYTIC VIRUS VECTOR AND USE THEREOF
US20240398939A1 (en) 2021-09-23 2024-12-05 Sagittarius Bio, Inc. Adenoviruses and methods for using adenoviruses
EP4499846A1 (en) * 2022-03-25 2025-02-05 Universität Zürich Adenoviral mediated targeting of activated immune cells
WO2024243578A1 (en) 2023-05-25 2024-11-28 Dispatch Biotherapeutics, Inc. Synthetic cancer antigens as targets for treating cancers
WO2025171383A2 (en) 2024-02-09 2025-08-14 Dispatch Biotherapeutics, Inc. Engineered cancer antigens and related methods and uses
WO2025171388A1 (en) 2024-02-09 2025-08-14 Dispatch Biotherapeutics, Inc. Engineered cancer antigens with modified domains and related methods and uses

Family Cites Families (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5358866A (en) 1991-07-03 1994-10-25 The United States Of America As Represented By The Department Of Health And Human Services Cytosine deaminase negative selection system for gene transfer techniques and therapies
US5846945A (en) 1993-02-16 1998-12-08 Onyx Pharmaceuticals, Inc. Cytopathic viruses for therapy and prophylaxis of neoplasia
FR2705361B1 (fr) 1993-05-18 1995-08-04 Centre Nat Rech Scient Vecteurs viraux et utilisation en thérapie génique.
FI951138L (fi) 1993-07-13 1995-04-13 Rhone Poulenc Rorer Sa Puuttellisia adenovirusvektoreita ja niiden käyttö geeniterapiassa
US5631236A (en) 1993-08-26 1997-05-20 Baylor College Of Medicine Gene therapy for solid tumors, using a DNA sequence encoding HSV-Tk or VZV-Tk
US5830686A (en) 1994-01-13 1998-11-03 Calydon Tissue-specific enhancer active in prostate
US5677170A (en) 1994-03-02 1997-10-14 The Johns Hopkins University In vitro transposition of artificial transposons
US5877011A (en) 1996-11-20 1999-03-02 Genzyme Corporation Chimeric adenoviral vectors
CN1242051A (zh) 1996-12-31 2000-01-19 昂尼克斯药物公司 用于肿瘤治疗和预防的致细胞病变病毒
US6420524B1 (en) 1997-02-20 2002-07-16 Johns Hopkins University School Of Medicine Gain of function mutations in ATP-dependent transposition proteins
US20030044384A1 (en) 1997-10-09 2003-03-06 Pro-Virus, Inc. Treatment of neoplasms with viruses
US6291214B1 (en) 1998-05-11 2001-09-18 Glaxo Wellcome Inc. System for generating recombinant viruses
US20020019051A1 (en) 1998-05-27 2002-02-14 Monika Lusky Chimeric adenoviral vectors
US20030017138A1 (en) 1998-07-08 2003-01-23 Menzo Havenga Chimeric adenoviruses
CN1110553C (zh) 1998-07-15 2003-06-04 杭州赛狮生物技术开发有限公司 基因工程腺病毒及其用途
AU767975B2 (en) 1998-09-11 2003-11-27 Genvec, Inc. Alternatively targeted adenovirus
CA2678259C (en) 1998-12-09 2016-10-18 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health & Human Services A recombinant vector expressing multiple costimulatory molecules and uses thereof
DK1681353T3 (da) 1999-05-17 2010-01-04 Crucell Holland Bv Af adenovirus afledte genoverförselsvehikler indeholdende mindste ét element af adenovirus type 35
WO2000073478A2 (en) 1999-06-01 2000-12-07 University Of Washington Recombinant adenoviral vectors expressing chimeric fiber proteins for cell specific infection and genome integration
US7396679B2 (en) 1999-11-15 2008-07-08 Onyx Pharmaceuticals, Inc. Oncolytic adenovirus
US7223593B2 (en) * 2000-01-21 2007-05-29 Biovex Limited Herpes virus strains for gene therapy
US7456009B2 (en) 2000-03-07 2008-11-25 Merck & Co., Inc. Adenovirus formulations
JP2003534806A (ja) 2000-05-31 2003-11-25 ジェンベク、インコーポレイティッド アデノウイルスベクターのターゲティングの方法および組成物
ATE449859T1 (de) 2001-01-04 2009-12-15 Goeran Wadell Virusvektor zur gentherapie
US20050175589A1 (en) 2001-07-13 2005-08-11 Btg International Limited Anti-neoplastic viral agents
AR039067A1 (es) 2001-11-09 2005-02-09 Pfizer Prod Inc Anticuerpos para cd40
EP1327688A1 (en) 2002-01-14 2003-07-16 Vereniging Voor Christelijk Wetenschappelijk Onderwijs Adenoviruses with enhanced lytic potency
CA2474777A1 (en) 2002-02-01 2003-08-07 Transgene S.A. Adenoviral vectors for modulating the cellular activities associated with pods
US20060147420A1 (en) 2004-03-10 2006-07-06 Juan Fueyo Oncolytic adenovirus armed with therapeutic genes
WO2003092594A2 (en) 2002-04-30 2003-11-13 Duke University Adeno-associated viral vectors and methods for their production from hybrid adenovirus and for their use
CN1705740B (zh) * 2002-10-15 2013-07-24 佩尔·松内·霍尔姆 具有反向基因表达的腺病毒及其应用
US20040167088A1 (en) 2003-02-25 2004-08-26 Genvec, Inc. Method of using adenoviral vectors with increased persistence in vivo
US20040213764A1 (en) 2003-03-28 2004-10-28 William Wold Adenovirus replication-competent vectors expressing trail
US20050136035A1 (en) * 2003-06-03 2005-06-23 Derek Ko Cell specific replication-competent viral vectors comprising a self processing peptide cleavage site
CN1934253A (zh) 2003-07-18 2007-03-21 昂尼克斯药物公司 用于治疗疾病的b亚组腺病毒载体
US20050186178A1 (en) * 2003-08-28 2005-08-25 Ennist David L. Oncolytic adenoviral vectors encoding GM-CSF
WO2005107474A2 (en) 2004-04-30 2005-11-17 Introgen Therapeutics, Inc. Oncolytic adenovirus armed with therapeutic genes
CA2567094C (en) 2004-05-26 2014-11-25 Schering Aktiengesellschaft Chimeric adenoviruses for use in cancer treatment
CN100361710C (zh) 2004-06-07 2008-01-16 成都康弘生物科技有限公司 肿瘤细胞专一表达免疫调节因子gm-csf的溶瘤性腺病毒重组体的构建及其应用
US20060292682A1 (en) * 2004-07-22 2006-12-28 Hawkins Lynda K Addition of transgenes into adenoviral vectors
CN101068933A (zh) * 2004-08-25 2007-11-07 细胞基因系统有限公司 用于肿瘤细胞增强转导的纤维修饰的腺病毒载体
CA2589602A1 (en) * 2004-09-01 2006-04-13 Genvec, Inc. Adenoviral vectors able to transduce apcs, potential use in immune response generation
EP1819823A2 (en) 2004-12-01 2007-08-22 Bayer Schering Pharma Aktiengesellschaft Generation of replication competent viruses for therapeutic use
CA2620495A1 (en) 2005-08-31 2007-03-08 Genvec, Inc. Adenoviral vector-based malaria vaccines
DE102005055128B4 (de) 2005-11-15 2015-04-02 Universität Rostock Viraler Vektor, dessen Verwendung zur Therapie von Leberzellkarzinomen und pharmazeutische Mittel umfassend den Vektor
ES2304281B1 (es) 2006-02-01 2009-08-12 Dnatrix Inc. Adenovirus oncoliticos para el tratamiento del cancer.
US8216819B2 (en) 2006-12-22 2012-07-10 Psioxus Therapeutics Limited Generation of oncolytic adenoviruses and uses thereof
CA2723580A1 (en) 2008-05-27 2009-12-03 Oncolytics Biotech Inc. Modulating interstitial pressure and oncolytic viral delivery and distribution
CN101381742A (zh) * 2008-10-23 2009-03-11 浙江理工大学 晚期启动子靶向性调控溶瘤腺病毒pCN305载体及其构建方法与应用
ES2385251B1 (es) * 2009-05-06 2013-05-06 Fundació Privada Institut D'investigació Biomèdica De Bellvitge Adenovirus oncolíticos para el tratamiento del cáncer.
WO2011043719A1 (en) * 2009-10-05 2011-04-14 Ya-Fang Mei Replicating viral vectors for gene therapy
KR101957616B1 (ko) 2010-08-16 2019-03-12 더 솔크 인스티튜트 포 바이올로지칼 스터디즈 아데노바이러스 조립 방법
CN103221423B (zh) * 2010-09-24 2015-09-30 昂克斯治疗有限公司 溶瘤腺病毒载体及与其相关的方法和用途
WO2012038606A1 (en) 2010-09-24 2012-03-29 Oncos Therapeutics Oy Oncolytic adenoviral vectors coding for monoclonal anti - ctla - 4 antibodies
WO2013074507A2 (en) 2011-11-14 2013-05-23 Regenerative Sciences, Llc Suspended particle delivery systems and methods
CN102586327B (zh) 2012-01-18 2013-09-11 陕西师范大学 一步法构建携带外源基因的d24纤维蛋白修饰的条件复制型腺病毒载体及其应用
WO2014138314A1 (en) 2013-03-05 2014-09-12 Baylor College Of Medicine Oncolytic virus
GB201322851D0 (en) 2013-12-23 2014-02-12 Psioxus Therapeutics Ltd Method
LT3021859T (lt) 2013-10-25 2018-06-11 Psioxus Therapeutics Limited Onkolitiniai adenovirusai su heterologiniais genais
CN106029889A (zh) 2013-11-22 2016-10-12 德那翠丝有限公司 表达免疫细胞刺激受体激动剂的腺病毒
GB201406608D0 (en) 2014-04-12 2014-05-28 Psioxus Therapeutics Ltd Virus
GB201510197D0 (en) * 2014-06-12 2015-07-29 Psioxus Therapeutics Ltd Method of treating ovarian cancer
GB201503500D0 (en) 2015-03-02 2015-04-15 Ucl Business Plc Cell
KR102626276B1 (ko) 2015-03-17 2024-01-17 틸트 바이오세러퓨틱스 오이 이-특이적인 항체를 암호화하는 종양붕괴성 아데노바이러스 및 이와 관련된 방법 및 용도
HRP20200439T1 (hr) 2015-04-30 2020-06-12 Psioxus Therapeutics Limited Onkolitički adenovirus koji kodira protein b7
MY193281A (en) 2015-12-17 2022-09-30 Psioxus Therapeutics Ltd Group b adenovirus encoding an anti-tcr-complex antibody or fragment
KR20180118198A (ko) 2016-03-18 2018-10-30 난트셀, 인크. 수지상 세포 감염을 위한 멀티모달 벡터(multimodal vector for dendritic cell infection)
KR102427563B1 (ko) 2016-08-29 2022-08-03 싸이오서스 테라퓨틱스 엘티디. 이중특이성 T 세포 활성화제(Bispecific T cell activator)가 보강된 아데노바이러스
GB201713765D0 (en) 2017-08-28 2017-10-11 Psioxus Therapeutics Ltd Modified adenovirus
AU2017345764A1 (en) 2016-10-20 2019-05-02 Alpine Immune Sciences, Inc. Secretable variant immunomodulatory proteins and engineered cell therapy
WO2018083258A1 (en) 2016-11-03 2018-05-11 Psioxus Therapeutics Limited Oncolytic adenovirus encoding at least three transgenes
WO2018083259A1 (en) 2016-11-03 2018-05-11 Psioxus Therapeutics Limited Oncolytic adenovirus encoding transgenes
WO2018083257A1 (en) 2016-11-03 2018-05-11 Psioxus Therapeutics Limited Oncolytic adenovirus encoding transgenes
CN118308311A (zh) * 2017-06-01 2024-07-09 阿卡米斯生物公司 溶瘤病毒和方法
GB201801614D0 (en) 2018-01-31 2018-03-14 Psioxus Therapeutics Ltd Formulation

Also Published As

Publication number Publication date
IL258044A (en) 2018-05-31
US10322152B2 (en) 2019-06-18
US20170266243A1 (en) 2017-09-21
CN108396015A (zh) 2018-08-14
ZA201801589B (en) 2019-10-30
US10124028B2 (en) 2018-11-13
AU2016256582A1 (en) 2017-11-16
CA2984038C (en) 2023-01-03
MX2017013684A (es) 2018-08-28
SG10201803081TA (en) 2018-06-28
HRP20200439T1 (hr) 2020-06-12
AU2018201446B2 (en) 2020-05-28
US20170056458A1 (en) 2017-03-02
JP2021176339A (ja) 2021-11-11
KR20250134212A (ko) 2025-09-09
US10849945B2 (en) 2020-12-01
SA517390260B1 (ar) 2021-11-10
PE20181140A1 (es) 2018-07-17
WO2016174200A1 (en) 2016-11-03
CN107690479B (zh) 2022-02-18
CO2017010831A2 (es) 2018-02-28
EP3288573A1 (en) 2018-03-07
JP6928380B2 (ja) 2021-09-01
EP3391892A1 (en) 2018-10-24
IL255286A0 (en) 2017-12-31
BR112017023171A2 (pt) 2018-07-17
IL284375A (en) 2021-07-29
KR20240032177A (ko) 2024-03-08
SA520412637B1 (ar) 2022-03-01
HUE048320T2 (hu) 2020-07-28
CY1122833T1 (el) 2021-05-05
IL258044B (en) 2021-07-29
US20180140649A1 (en) 2018-05-24
EA037611B1 (ru) 2021-04-21
IL284375B (en) 2022-07-01
US20210338753A1 (en) 2021-11-04
JP6931229B2 (ja) 2021-09-01
CN108396015B (zh) 2022-02-18
AU2016256582B2 (en) 2020-10-29
PT3288573T (pt) 2020-03-25
JP2018514199A (ja) 2018-06-07
CL2017002731A1 (es) 2018-06-08
LT3288573T (lt) 2020-03-25
SG10201901482XA (en) 2019-03-28
CL2018000587A1 (es) 2018-08-10
US10548929B2 (en) 2020-02-04
JP7162929B2 (ja) 2022-10-31
PH12017501942A1 (en) 2018-03-19
CA2984038A1 (en) 2016-11-03
DK3288573T3 (da) 2020-03-16
AU2018201446A1 (en) 2018-03-29
ES2780366T3 (es) 2020-08-25
US11000559B2 (en) 2021-05-11
KR102643574B1 (ko) 2024-03-06
PL3288573T3 (pl) 2020-05-18
AU2016256582A8 (en) 2018-01-18
EP3288573B1 (en) 2020-02-12
KR20180022638A (ko) 2018-03-06
JP2018139586A (ja) 2018-09-13
KR102854512B1 (ko) 2025-09-04
BR122018004815A2 (pt) 2019-09-10
HK1249009A1 (en) 2018-10-26
AU2020223665A1 (en) 2020-09-10
IL255286B (en) 2021-01-31
SI3288573T1 (sl) 2020-06-30
RS60105B1 (sr) 2020-05-29
US20190076493A1 (en) 2019-03-14
CN107690479A (zh) 2018-02-13
MY183703A (en) 2021-03-09
KR20180118249A (ko) 2018-10-30
SG11201708604TA (en) 2017-11-29
EA201791971A1 (ru) 2018-04-30
SMT202000222T1 (it) 2020-05-08
US20180042973A1 (en) 2018-02-15

Similar Documents

Publication Publication Date Title
PE20181140A1 (es) Adenovirus oncolitico que codifica una proteina b7
CO2018005945A2 (es) Adenovirus del grupo b que codifica un anticuerpo contra el complejo tcr o fragmento de este
PE20190563A1 (es) Genes de mini-distrofina optimizados y casetes de expresion y su uso
UY35964A (es) Anticuerpos humanos para pd?1
PE20160244A1 (es) Anticuerpos contra el inhibidor del activador de plasminogeno tipo 1 (pai-1) y usos de los mismos
AR100419A1 (es) Vectores de virus adenoasociados para el tratamiento de trastornos de almacenamiento lisosómico
MX2017004664A (es) Conjugados de farmacos de anticuerpos modificados mediante glicoingenieria.
BR112019002646A2 (pt) composições de poxvírus quimérico e usos das mesmas
CO2017000506A2 (es) Receptor quimérico de antígeno cll-1
MX384795B (es) Vectores que comprenden secuencias de polinucleotidos rellenadoras/de relleno y metodos de uso.
MX2017002205A (es) Receptor quimerico de antigeno (car) anti-cd123 para uso en el tratamiento de cancer.
MX2018007237A (es) Proteinas de cápside modificadas para un suministro mejorado de vectores de parvovirus.
UY35965A (es) Anticuerpos humanos contra pd?l1
AR102527A1 (es) Vacunas terapéuticas para hpv16
UY35718A (es) Anticuerpos anti-csf-1r: métodos de expresión de los mismos.
BR112019004711A2 (pt) receptores de antígeno quiméricos compreendendo domínios de fibronectina tipo iii específicos para bcma e usos dos mesmos
CL2015003199A1 (es) Peptidos terapeuticos
MX2019006722A (es) Construcciones de adenovirus de chimpance con antigenos de lyssavirus.
MX2022000222A (es) Vectores virales recombinantes que contienen la proteina menor del virus del sindrome reproductor y respiratorio porcino (prrsv) y sus metodos de elaboracion y uso.
MX362515B (es) Proteinas péptidos y métodos de uso de las plantas antifúngicas.
MX2018000845A (es) Vector vírico orf recombinante.
MX2020001287A (es) Receptor de linfocitos t (tcrs) especificos de braf y usos de los mismos.
NZ752275A (en) Compositions and methods for enhancing the stability of transgenes in poxviruses
EA201890595A1 (ru) Онколитический аденовирус, кодирующий белок b7
MY185846A (en) Oncolytic adenovirus encoding a b7 protein